✦ LIBER ✦

Pharmacokinetics and Safety of Concentration-Controlled Oral Zidovudine Therapy

✍ Scribed by Dr. Edward P. Acosta; Dr. Keith Henry; Dr. Linda M. Page; Dr. Alejo Erice; Dr. Henry H. Balfour Jr.; Dr. Courtney V. Fletcher

Book ID: 112113573
Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 660 KB
Volume: 17
Category: Article
ISSN: 0277-0008
DOI: 10.1002/j.1875-9114.1997.tb03052.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of zidovudine and didan

Pharmacokinetics of zidovudine and didanosine during combination therapy

✍ Gene D. Morse; Mark J. Shelton; Monto Ho; Linda Bartos; Mary DeRemer; Margaret R 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 346 KB

Pharmacokinetics and safety of fibrinoge

Pharmacokinetics and safety of fibrinogen concentrate

✍ M. J. MANCO-JOHNSON; D. DIMICHELE; G. CASTAMAN; S. FREMANN; S. KNAUB; U. KALINA 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB

Pharmacokinetics of orally administered

Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults

✍ U. Wintergerst; B. Rolinski; Gundula Notheis; B. H. Belohradsky; F. -D. Goebel; 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 English ⚖ 772 KB

Pharmacokinetics of oral zidovudine admi

Pharmacokinetics of oral zidovudine administered during labour: a preliminary study

✍ M Mirochnick; JH Rodman; BL Robbins; A Fridland; J Gandía; J Hitti; A Bardeguez; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

Safety and tolerance of intermittent int

Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients

✍ Ross E. McKinney Jr.; Philip A. Pizzo; Gwendolyn B. Scott; Wade P. Parks; Mary A 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 689 KB

Pharmacokinetics and safety of single or

Pharmacokinetics and safety of single oral doses of lomefloxacin

✍ Dr. Irwin S. Morse 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 444 KB 👁 2 views

The pharmacokinetics of 100 mg, 200 mg, 400 mg, 600 mg, and 800 mg of lomefloxacin, a quinolone antimicrobial, were examined in a single sequential rising dose, placebocontrolled, crossover study. Each of 30 healthy male subjects (6 per group) received placebo and one dose of lomefloxacin, separated